Light-Activated gene therapy offers new hope for rare blindness
NCT ID NCT03326336
First seen Mar 04, 2026 · Last updated May 16, 2026 · Updated 12 times
Summary
This study tests a new treatment for retinitis pigmentosa, a genetic eye disease that causes vision loss. Ten adults receive a single injection of gene therapy into the eye, then use special glasses that stimulate the treated cells with light. The goal is to see if the treatment is safe and can improve vision.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SYNDROMIC RETINITIS PIGMENTOSA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Hospitalier National d'Ophtalmologie (CHNP) des Quinze-Vingts
Paris, 75012, France
-
Moorfields Eye Hospital NHS Foundation Trust, 162 City Road
London, United Kingdom
-
UPMC Eye Center
Pittsburgh, Pennsylvania, 15213, United States
Conditions
Explore the condition pages connected to this study.